首页> 外文期刊>Oncology reports >Ultrasound-targeted microbubble destruction-mediated downregulation of CD133 inhibits epithelial-mesenchymal transition, stemness and migratory ability of liver cancer stem cells.
【24h】

Ultrasound-targeted microbubble destruction-mediated downregulation of CD133 inhibits epithelial-mesenchymal transition, stemness and migratory ability of liver cancer stem cells.

机译:超声靶向微泡破坏介导的CD133下调抑制了肝癌干细胞的上皮-间质转化,干性和迁移能力。

获取原文
获取原文并翻译 | 示例
           

摘要

Hepatocellular carcinoma (HCC) is an aggressive disease with a poor outcome due to the high incidence of metastasis. Cancer stem cells (CSCs) have been identified to be responsible for tumor progression and may be generated by epithelial-mesenchymal transition (EMT) characteristics. CD133 is a specific surface marker for liver cancer stem cells (LCSCs), which is also considered as an important functional factor for tumorigenesis and overall survival in HCC. Ultrasound-targeted microbubble destruction (UTMD) has recently been used as a novel, safe and effective gene transfection technology. The aim of the present study was to elucidate the regulatory mechanism of CD133 and EMT in LCSCs and whether the UTMD-based shRNA delivery system facilitated gene delivery in LCSCs. In the present study, CD133+?cells were isolated from the SMMC-7721 HCC cell line and then transfected with shCD133 mediated by UTMD and liposomes, respectively. Compared to the liposomes group, the UTMD group resulted in significantly improved transfection efficiency. The downregulation of CD133 reversed the EMT program, attenuated self-renewal, proliferation and migration of CD133+ LCSCs and suppressed the growth of CSC tumor xenografts. Additionally, the downregulation of CD133 led to downregulation of the nuclear factor-κB (NF-κB) pathway. The present study demonstrated that CD133 plays a critical role in the regulation of the EMT process, tumor-initiating properties and migratory ability of LCSCs. The UTMD technique targeted for CD133 downregulation may be examined as a potential therapeutic strategy for HCC.
机译:肝细胞癌(HCC)是一种侵袭性疾病,由于转移发生率高,因此预后较差。癌症干细胞(CSC)已被鉴定为导致肿瘤进展的原因,可能是由上皮-间质转化(EMT)特性产生的。 CD133是肝癌干细胞(LCSC)的特定表面标记,也被认为是HCC肿瘤发生和总体存活的重要功能因子。超声靶向微泡破坏(UTMD)最近已被用作一种新颖,安全和有效的基因转染技术。本研究的目的是阐明LCSCs中CD133和EMT的调控机制,以及基于UTMD的shRNA递送系统是否有助于LCSCs中的基因递送。在本研究中,从SMMC-7721 HCC细胞系中分离出CD133 +细胞,然后分别用UTMD和脂质体介导的shCD133转染。与脂质体组相比,UTMD组可显着提高转染效率。 CD133的下调逆转了EMT程序,减弱了CD133 + LCSCs的自我更新,增殖和迁移,并抑制了CSC肿瘤异种移植物的生长。另外,CD133的下调导致核因子-κB(NF-κB)途径的下调。本研究表明,CD133在调控EMT过程,LCSCs的肿瘤起始特性和迁移能力中起着至关重要的作用。可以将针对CD133下调的UTMD技术作为HCC的潜在治疗策略进行检查。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号